News Daily News Weight Regained Within 18 Months of Stopping GLP-1 Drugs Michael O'Riordan January 08, 2026
News Daily News SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide Michael O'Riordan December 18, 2025
News Daily News Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT Michael O'Riordan July 31, 2025
News Conference News European Congress on Obesity 2025 SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly Michael O'Riordan May 14, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Daily News CMS Proposal Would Expand Medicare, Medicaid Coverage for GLP-1 Drugs Todd Neale November 27, 2024
News Daily News Many Patients Quit Taking GLP-1 Drugs: Understanding Why Is Key Todd Neale November 13, 2024
News Conference News EACTS 2024 Will Semaglutide Change Cardiac Surgery? It Already Has Yael L. Maxwell October 10, 2024
News Conference News SCCT 2024 Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients Todd Neale July 22, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for December 2023 Caitlin E. Cox December 28, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Features Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar L.A. McKeown May 12, 2023
News Daily News Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS Todd Neale May 14, 2021
News Daily News Most Secondary Prevention Patients Are Eligible for Multiple Drugs Michael O'Riordan January 03, 2020